3-Vessel CAD: Surgery vs. Stenting and Prognosis

Three-vessel coronary artery disease, often written as 3-vessel CAD or 3VD, means that all three of the heart’s major coronary arteries have significant narrowing from plaque buildup. Those arteries are the left anterior descending (LAD), the left circumflex (LCx), and the right coronary artery (RCA). Because no single remaining artery can compensate if one fails, 3-vessel CAD sits near the top of the severity scale for coronary heart disease and typically demands some form of revascularization, whether surgical or catheter-based. The condition’s management has become one of the most studied and debated topics in cardiology, and the choices involved are rarely straightforward.

How 3-Vessel CAD Is Detected

Most people learn they have 3-vessel disease after a coronary angiogram, the gold-standard test where dye is injected directly into the coronary arteries under X-ray. But noninvasive imaging has narrowed the gap. Ultra-high-resolution coronary CT angiography (CCTA) now achieves per-patient sensitivity of 100% for detecting significant blockages when compared head-to-head with invasive angiography, though it slightly overestimates the degree of narrowing by a few percentage points on average.¹ That overestimation means CT can flag a vessel as severely blocked when it is only moderately narrowed, so borderline cases still often need invasive confirmation.

CT-based imaging has also been validated as a tool for heart-team decision-making. When specialist teams used CCTA to score lesion complexity and decide between surgery and stenting, their treatment recommendations agreed with those made from conventional angiography about 82% of the time.² That level of agreement means many patients can get an initial road map from a CT scan before anyone threads a catheter into their arteries.

Beyond anatomy, physicians now increasingly care about whether a blockage actually starves the heart muscle of blood. A measurement called fractional flow reserve (FFR) gauges pressure drop across a narrowing during catheterization. A newer, less invasive cousin, CT-derived FFR (FFRCT), applies computer modeling to a standard CT scan. In patients with multivessel disease, FFRCT showed a sensitivity of 95% for identifying blockages that genuinely limit blood flow.³ However, in a randomized trial focused on multivessel CAD, an FFR-guided treatment strategy did not reduce the risk of heart attacks or death at one year compared with standard angiography-guided care.⁴ The technology is clearly good at identifying which blockages matter, but proving that acting on those measurements improves hard outcomes has been more elusive.

Surgery Versus Stenting

The question that dominates 3-vessel CAD management is whether to perform coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with drug-eluting stents. Decades of evidence now favor CABG for most patients with 3-vessel disease, though the margin varies by patient profile.

A meta-analysis pooling individual patient data from major randomized trials found that composite cardiovascular events were lower with surgery than with stenting. The difference was driven mainly by fewer heart attacks, with CABG also requiring far fewer repeat procedures.⁵ That analysis found a significant CABG advantage in multivessel disease specifically, while results for isolated left-main disease were closer to a wash.

The survival advantage of surgery tends to widen over time. In a large propensity-matched registry study, survival was similar between CABG and stenting at one year. By five years, patients who had surgery had a roughly 7-percentage-point survival advantage, and the overall risk of death was about 29% lower in the surgical group.⁶ A separate propensity-matched study that specifically focused on 3-vessel CAD found a similar story: after matching for clinical characteristics, PCI with newer-generation stents carried roughly two to three times the risk of death compared with CABG, and the need for repeat procedures was dramatically higher with stents.⁷

That said, one registry study of over 3,000 patients treated between 2003 and 2005 found that after adjusting for baseline differences, long-term mortality was similar between drug-eluting stents and CABG.⁸ This helps explain why PCI remains a reasonable option for certain patients, particularly those with less complex lesion patterns or higher surgical risk. The benefit of CABG over stents was especially pronounced in patients with diabetes and in those with the highest lesion complexity scores.⁹

Why Lesion Complexity Matters So Much

Not all 3-vessel disease is equal. The SYNTAX score, which grades the number, location, and difficulty of coronary blockages on a standard scale, has become the primary tool for deciding who benefits most from surgery. When lesion complexity is high, CABG provides substantially better angina relief than stenting. A five-year analysis of quality of life found that the advantage in angina reduction grew as SYNTAX scores rose, reinforcing clinical guidelines that strongly prefer surgery for the most complex cases.¹⁰

Newer versions of the scoring system incorporate clinical variables like age, kidney function, and lung disease, yielding more individualized risk predictions. In a pilot study comparing SYNTAX Score II and SYNTAX Score 2020 in 3-vessel disease patients, patients routed to CABG by the heart team had higher predicted event rates than those enrolled in PCI trials, confirming that clinicians are already using these tools to steer the sickest patients toward surgery.¹¹

Complete Versus Incomplete Revascularization

Whether you open one blocked artery or all three makes a meaningful difference. A large meta-analysis covering nearly 90,000 patients found that complete revascularization, meaning every significant blockage is addressed, was tied to roughly 29% lower long-term mortality compared with leaving some blockages untreated. The mortality benefit held regardless of whether revascularization was done by surgery or by stenting.¹²

The importance of completeness was also evident in older data from the landmark Coronary Artery Surgery Study (CASS) registry. Among patients with 3-vessel disease and impaired heart function, those who received grafts to three or more vessels had substantially better survival than those who received fewer grafts. In patients with weak hearts, six-year survival was about 69% with more complete grafting versus 45% with less complete grafting.¹³ The message is consistent across eras and study designs: when technically feasible, opening all diseased vessels matters.

Choosing the Right Grafts for Surgery

If surgery is the chosen route, what the surgeon connects to your arteries makes a real difference in the long run. The internal mammary artery (also called the internal thoracic artery) is the gold standard conduit, and virtually all modern CABG operations use the left internal mammary artery to bypass the LAD. But there is strong evidence that using additional arterial grafts, rather than relying on veins from the leg for the remaining vessels, further improves long-term survival.

A study of over 8,600 multivessel-disease patients found that those who received multiple arterial grafts had 15-year survival rates of about 70%, compared with 60% for those who got a single mammary artery plus vein grafts. In multivariate analysis, receiving multiple arterial grafts remained an independent predictor of better survival.¹⁴ A separate 20-year single-institution analysis found that the best survival times were seen in patients who received bilateral internal mammary arteries plus a radial artery graft, with an estimated mean survival approaching 19 years.¹⁵

Despite this evidence, many patients worldwide still receive vein grafts for all vessels other than the LAD. Veins are technically easier to harvest and handle, the operation is shorter, and some surgeons are cautious about the slightly higher wound-infection risk that comes with harvesting both mammary arteries, especially in patients with diabetes or obesity. Still, for younger patients and those expected to live long enough to see vein grafts deteriorate, pushing for arterial grafts is a conversation worth having with your surgeon.

The Role of Diabetes

Diabetes and 3-vessel CAD go hand in hand. Diabetic patients tend to develop more widespread and more severe coronary disease. In a comparative analysis, about 36% of diabetic patients had 3-vessel involvement versus roughly 25% of non-diabetic patients.¹⁶ Diabetic patients also tend to have more diffuse disease, meaning the plaque spreads along the length of a vessel rather than concentrating in a single spot. This diffuse pattern is harder to stent effectively, which is one reason why the CABG advantage over PCI is particularly large in people with diabetes.¹⁷

Blood sugar control after revascularization also shapes long-term outcomes. A cohort study of patients with diabetes and 3-vessel disease found a J-shaped relationship between hemoglobin A1c (a marker of average blood sugar) and the risk of death or major cardiac events. The sweet spot was an A1c between about 6.0% and 6.4%. In patients younger than 70, higher A1c meant progressively worse outcomes. But in patients 70 and older, pushing A1c below 6% was actually associated with a higher risk of adverse events.¹⁸ This finding aligns with broader geriatric medicine research showing that aggressive blood sugar lowering in older adults can cause dangerous hypoglycemia without improving cardiovascular outcomes.

Three-Vessel Disease During a Heart Attack

When someone arrives at the hospital with a heart attack and is found to have 3-vessel disease, the management question becomes more urgent and more complicated. In cardiogenic shock, where the heart is too weak to pump enough blood to the body, the instinct might be to open all blocked arteries immediately. But evidence from a large US cohort study spanning 2009 to 2018 found that multivessel PCI during the acute episode was actually associated with worse in-hospital mortality compared with treating only the artery responsible for the heart attack, particularly in patients with ST-elevation heart attacks.¹⁹

Current practice reflects this caution. An international survey of interventional cardiologists found that the most common approach (about 55%) was to stent only the culprit artery during the emergency and stage further procedures later. A large proportion of respondents (about 47%) believed that initial PCI followed by staged CABG for the remaining vessels would produce the best outcomes.²⁰ The general principle: stabilize first, then plan complete revascularization once the patient is out of immediate danger.

Older Adults With 3-Vessel Disease

Age complicates the treatment calculus. A 10-year follow-up analysis of elderly patients (typically 75 and older) with complex coronary disease found that mortality was not significantly different between PCI and CABG, and neither was quality of life at five years. The estimated life-expectancy difference between the two strategies was only about two months in favor of surgery, which was not statistically meaningful.²¹ This stood in contrast to younger patients, where CABG had a clearer advantage in reducing major events.

Even so, completeness of revascularization still matters in older adults. A subanalysis of elderly patients with multivessel disease who underwent PCI found that those who achieved complete revascularization had a major adverse event rate of about 7%, compared with about 21% in those who received incomplete treatment.²² So while the choice between CABG and PCI may be more flexible in older patients, the goal of treating all significant blockages remains important regardless of which approach is used.

Hybrid Revascularization

A newer strategy tries to combine the best of both worlds. Hybrid coronary revascularization pairs a minimally invasive surgical bypass of the LAD, typically using a robotic or small-incision technique, with stenting of the remaining vessels.²³ The rationale is straightforward: the LAD is the most critical artery, and a mammary artery graft to the LAD is the most durable connection in cardiac surgery. The other vessels, which often have less complex lesions, can be effectively managed with modern stents.

A 10-year follow-up study found that hybrid revascularization performed similarly to off-pump CABG and significantly outperformed PCI alone in terms of major cardiac events and functional status.²⁴ An advanced version using robotic surgery with bilateral internal mammary artery grafts reported 98% early graft patency and 94% freedom from major events at eight-year follow-up.²⁵ Hybrid approaches remain relatively uncommon because they require a center with both advanced interventional cardiology and minimally invasive cardiac surgery expertise, but they offer a compelling option for the right patient.

Medical Therapy Is Not Optional

Regardless of whether someone undergoes CABG, PCI, or a hybrid procedure, guideline-directed medical therapy is the foundation. Statins, blood pressure medications, antiplatelet drugs, and lifestyle modifications slow the progression of atherosclerosis and prevent the blood clots that cause heart attacks.²⁶ Revascularization addresses the plumbing problem, but medication addresses the underlying disease process. Skipping the medications after a procedure is one of the most common and most preventable mistakes patients make.

After revascularization, cardiac rehabilitation also plays a meaningful role, particularly for patients who did not receive complete revascularization. A study of patients with multiple coronary lesions who underwent partial revascularization found that a structured rehabilitation program improved exercise capacity, quality of life, and markers of blood-vessel health over one year.²⁷ For patients who cannot have all their vessels fixed, supervised exercise and risk-factor management become especially important bridges.

Long-Term Prognosis and What Shapes It

Survival with 3-vessel disease depends on a web of factors beyond just the arteries themselves. A 15-year follow-up study identified age, diabetes, body mass index, low heart-pumping function, and the presence of left-main narrowing as the strongest independent predictors of death. Interestingly, the study also found that a genetic variation in the promoter region of the interleukin-6 gene influenced survival, suggesting that how aggressively someone’s body produces inflammation can tip the balance over years and decades.²⁸

Acute metabolic stress also matters. A large cohort study of 3-vessel disease patients found that a high stress hyperglycemia ratio, which captures how much blood sugar spikes during hospitalization relative to a person’s usual levels, roughly doubled the risk of cardiovascular events. This association held in both diabetic and non-diabetic patients.²⁹ The finding suggests that how the body handles metabolic stress during a cardiac event is itself a marker of vulnerability, independent of whether someone carries a diabetes diagnosis.

Cost Considerations

CABG costs more up front than PCI. In the EXCEL trial, the initial hospitalization for surgery ran about $32,000 compared with roughly $20,000 for stenting. At five years, cumulative costs were still about $20,000 higher with CABG.³⁰ A Dutch analysis found a similar pattern: CABG was more expensive initially and remained so over five years, but when results were projected over a full lifetime, surgery was considered economically attractive because the gains in life expectancy and quality of life justified the added expense.³¹ PCI patients, meanwhile, incur more costs downstream from repeat hospitalizations and additional stent procedures. The practical takeaway: stenting is cheaper to start but can catch up over time, while surgery is a bigger initial investment that tends to pay for itself in durability.

Focal Versus Diffuse Plaque Patterns

The character of the plaque itself varies considerably among people with multivessel disease and may influence which lesions are most dangerous. Imaging research comparing focal disease (a discrete, tight blockage) with diffuse disease (plaque spread along the vessel wall) found strikingly different plaque compositions. Focal lesions were far more likely to contain lipid-rich, thin-capped plaques, the type most prone to rupturing and triggering a heart attack. Diffuse disease, by contrast, tended toward more calcified, stable plaque.³² This distinction is clinically relevant: a patient whose 3-vessel disease consists mostly of focal, lipid-rich lesions may face a higher near-term risk of a heart attack even if the overall degree of narrowing looks moderate. Conversely, heavily calcified diffuse disease may be more stable but harder to treat with stents or even surgical grafts because there is no clean landing zone for either.